172 related articles for article (PubMed ID: 31482294)
1. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Sawazaki H; Araki D; Kitamura Y; Yagi K
World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
4. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
[TBL] [Abstract][Full Text] [Related]
7. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.
Hopmans SN; Duivenvoorden WC; Werstuck GH; Klotz L; Pinthus JH
Urol Oncol; 2014 Nov; 32(8):1126-34. PubMed ID: 25242517
[TBL] [Abstract][Full Text] [Related]
8. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
[TBL] [Abstract][Full Text] [Related]
9. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
11. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
Low Urin Tract Symptoms; 2017 May; 9(2):82-88. PubMed ID: 28394498
[TBL] [Abstract][Full Text] [Related]
12. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
13. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
[TBL] [Abstract][Full Text] [Related]
14. Combined androgen blockade for salivary gland carcinoma.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
[No Abstract] [Full Text] [Related]
15. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
16. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
Anderson J; Al-Ali G; Wirth M; Gual JB; Gomez Veiga F; Colli E; van der Meulen E; Persson BE
Urol Int; 2013; 90(3):321-8. PubMed ID: 23258223
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.
McNeel DG; Smith HA; Eickhoff JC; Lang JM; Staab MJ; Wilding G; Liu G
Cancer Immunol Immunother; 2012 Jul; 61(7):1137-47. PubMed ID: 22210552
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
Amato R; Stepankiw M; Gonzales P
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1629-34. PubMed ID: 23604530
[TBL] [Abstract][Full Text] [Related]
20. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
